SCHEMBL7963498

SCHEMBL7963498

CC(C)N(C(C)C)C(C)CC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 1/20 0.39
TDP1 Q9NUW8 2/20 0.38
CACNA2D1 P54289 2/20 0.37
CACNB3 P54284 1/20 0.37
CACNA1C Q13936 1/20 0.37
PGR P06401 1/20 0.37
ADRA1A P35348 1/20 0.37
HTR2B P41595 1/20 0.37
CACNA2D2 Q9NY47 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 1/20 0.34
GABRR1 P24046 2/20 0.33
LMNA P02545 1/20 0.33
MME P08473 2/20 0.32
GABRP O00591 2/20 0.32
GABRD O14764 2/20 0.32
GABRA1 P14867 2/20 0.32
GABRB1 P18505 2/20 0.32
GABRG2 P18507 2/20 0.32
GABRB3 P28472 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19729247 0.81 SLC22A6 (0.41) SLC22A6TDP1CACNA2D1CACNB3CACNA1C
SCHEMBL19729246 0.77 SLC22A6 (0.43) SLC22A6TDP1CACNA2D1CACNB3CACNA1C
SCHEMBL22384141 0.77 SLC22A6 (0.38) SLC22A6TDP1CACNA2D1CACNB3CACNA1C
SCHEMBL105805 0.76
SCHEMBL103866 0.76
SCHEMBL19729262 0.75 SLC22A6 (0.36) SLC22A6TDP1CACNA2D1CACNB3CACNA1C
SCHEMBL19729271 0.75 TDP1 (0.40) SLC22A6TDP1CACNA2D1CACNB3CACNA1C
SCHEMBL19729273 0.75 SLC22A6 (0.36) SLC22A6TDP1CACNA2D1CACNB3CACNA1C
SCHEMBL6435732 0.75 TDP1 (0.40) SLC22A6TDP1CACNA2D1CACNB3CACNA1C
SCHEMBL7000054 0.74 SLC22A6 (0.39) SLC22A6TDP1CACNA2D1CACNB3CACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104447707-B Hepatitis c virus inhibitors 百时美施贵宝公司 2017-04-12 CN disclosed
CN-103429607-B There is the triterpenoid that C-17 and C-3 of HIV maturation inhibit activities is modified BRISTOL-MYERS SQUIBB CO. (US) 2016-02-17 CN disclosed
CN-104447707-A Hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2015-03-25 CN disclosed
CN-101558059-B Hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2014-12-03 CN disclosed
CN-103429607-A C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity BRISTOL MYERS SQUIBB CO 2013-12-04 CN disclosed
CN-102007122-B Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2013-09-04 CN disclosed
CN-102007122-A Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2011-04-06 CN disclosed
CN-101558059-A Hepatitis C virus inhibitors BRISTOL MYERS SQUIBB CO (US) 2009-10-14 CN disclosed
US-6215016-B1 HEMATOPOIETIC AGENTS; PREVENTING CYTOPENIA TORAY INDUSTRIES, INC. (JP) 2001-04-10 US disclosed
EP-0841063-A1 KETONE DERIVATIVES AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 1998-05-13 EP disclosed